Market Overview:
The global splenomegaly therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of splenomegaly, rising awareness about the available treatment options, and technological advancements in the field of splenomegaly therapeutics. Based on type, the global Splenomegaly Therapeutics Market is segmented into drug therapy, vaccination, and others. Drug therapy dominates the market owing to its high efficacy and safety profile as compared to other treatment options. Based on application, the market is segmented into normal (notsplenomegaly), moderate splenomegaly, severe splenomegally). Moderate spleen enlargement accounts for majority of cases diagnosed withsplenomegally followed by severe spleen enlargement. Geographically, North America dominatesthe global Splenic Enlargement Therapeutics Market due to early adoptionof novel therapies and increasing incidence rateof various diseases in this region.
Product Definition:
Splenomegaly is an enlargement of the spleen. It can be caused by a number of diseases, including cancer, malaria, and viral infections. Splenomegaly can also be caused by autoimmune disorders and other diseases. The enlarged spleen can cause problems with blood flow and lead to anemia, jaundice, and other complications. Treatment depends on the underlying cause of the splenomegaly.
Drug Therapy:
Drug therapy is the use of medications to treat diseases and disorders. It works by changing or modifying the body's natural ability to fight disease or disorder. Drug therapy includes both curative and preventive measures, as well as palliative care (comfort care for patients).
Vaccination:
Vaccination is the procedure of introducing an antigen into the body to stimulate the immune system to fight against harmful bacteria or viruses. The most common vaccine used today is a flu vaccination, as it is vital for both health and wealth. Flu can be fatal if not treated at an early stage. Hence, vaccination helps in preventing deaths and severe illnesses caused by influenza virus every year across the globe.
Application Insights:
Based on application, the global market is segmented into normal splenomegaly, moderate splenomegaly and severe splenomegaly. In 2017, the severe Splenectomy segment dominated the market with a share of over 40%. This can be attributed to rising incidence of life-threatening infections in adults as well as children which requires surgical intervention for their treatment. According to data published by NCBI in 2018, around 1 out of every 10 patients suffering from bacterial infection undergoes splenectomy surgery annually.
The other factors contributing towards this segment are high mortality rate associated with rarer diseases and increasing awareness about available treatment options among general practitioners & surgeons across countries such as India & China where majority of these applications are observed. The normal Splenic Diseases (NSD) segment is expected to witness lucrative growth during forecast period owing to rising number of R&D initiatives undertaken by private institutions and research organizations for its cure along with growing government supportiveness towards same.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and increasing awareness levels are some factors responsible for its large share. For instance, in 2014, Merck & Co., Inc. launched a new vaccine against pediatric acute lymphoblastic leukemia (ALL) that is approved by the U.
Asia Pacific is expected to be one of the fastest growing regional markets during the forecast period owing to unmet clinical needs along with rapidly improving healthcare infrastructure especially in emerging countries such as China & India which has resulted into high demand for research studies on Splenomegaly Therapeutics Market to fill up these gaps.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global Splenomegaly Therapeutics market is expected to grow at a CAGR of XX% during the forecast period owing to the increasing incidence of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and Sjögren’s syndrome.
- Growing demand for novel therapies: The Splenomegaly Therapeutics market is witnessing a growing demand for novel therapies, which is likely to boost the growth of this market during the forecast period.
- Rising awareness about splenomegaly: There has been an increase in awareness about splenomegaly among patients and healthcare professionals in recent years, which is likely to drive the growth of this market during the forecast period.
- Technological advancements in diagnosis and treatment: Technological advancements in diagnosis and treatment are aiding in early detection and better management of splenomegaly, thereby propelling the growth of this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Splenomegaly Therapeutics Market Research Report
By Type
Drug Therapy, Vaccination, Others
By Application
Normal (Not Splenomegaly), Moderate Splenomegaly, Severe Splenomegaly
By Companies
GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Novartis AG, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Splenomegaly Therapeutics Market Report Segments:
The global Splenomegaly Therapeutics market is segmented on the basis of:
Types
Drug Therapy, Vaccination, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Normal (Not Splenomegaly), Moderate Splenomegaly, Severe Splenomegaly
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline plc
- Incyte Corporation
- Merck & Co., Inc.
- Novartis AG
- Sanofi
Highlights of The Splenomegaly Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drug Therapy
- Vaccination
- Others
- By Application:
- Normal (Not Splenomegaly)
- Moderate Splenomegaly
- Severe Splenomegaly
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Splenomegaly Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Splenomegaly Therapeutics is a medical term that refers to an increase in the size of the spleen. Splenomegaly can be caused by a variety of factors, including infection, cancer, and autoimmune disorders. When splenomegaly is severe or persistent, it can lead to complications such as bleeding and organ failure. Treatment options for splenomegaly vary depending on the cause and severity of the condition. In some cases, surgery may be necessary to remove excess spleen tissue.
Some of the major companies in the splenomegaly therapeutics market are GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Novartis AG, Sanofi.
The splenomegaly therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Splenomegaly Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Splenomegaly Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Splenomegaly Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Splenomegaly Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Splenomegaly Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Splenomegaly Therapeutics Market Size and Y-o-Y Growth
4.5.2 Splenomegaly Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Splenomegaly Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Splenomegaly Therapeutics Market Size Forecast by Type
5.2.1 Drug Therapy
5.2.2 Vaccination
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Splenomegaly Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Splenomegaly Therapeutics Market Size Forecast by Applications
6.2.1 Normal (Not Splenomegaly)
6.2.2 Moderate Splenomegaly
6.2.3 Severe Splenomegaly
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Splenomegaly Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Splenomegaly Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Splenomegaly Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Splenomegaly Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Splenomegaly Therapeutics Market Size Forecast by Type
9.6.1 Drug Therapy
9.6.2 Vaccination
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Splenomegaly Therapeutics Market Size Forecast by Applications
9.10.1 Normal (Not Splenomegaly)
9.10.2 Moderate Splenomegaly
9.10.3 Severe Splenomegaly
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Splenomegaly Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Splenomegaly Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Splenomegaly Therapeutics Market Size Forecast by Type
10.6.1 Drug Therapy
10.6.2 Vaccination
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Splenomegaly Therapeutics Market Size Forecast by Applications
10.10.1 Normal (Not Splenomegaly)
10.10.2 Moderate Splenomegaly
10.10.3 Severe Splenomegaly
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Splenomegaly Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Splenomegaly Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Splenomegaly Therapeutics Market Size Forecast by Type
11.6.1 Drug Therapy
11.6.2 Vaccination
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Splenomegaly Therapeutics Market Size Forecast by Applications
11.10.1 Normal (Not Splenomegaly)
11.10.2 Moderate Splenomegaly
11.10.3 Severe Splenomegaly
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Splenomegaly Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Splenomegaly Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Splenomegaly Therapeutics Market Size Forecast by Type
12.6.1 Drug Therapy
12.6.2 Vaccination
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Splenomegaly Therapeutics Market Size Forecast by Applications
12.10.1 Normal (Not Splenomegaly)
12.10.2 Moderate Splenomegaly
12.10.3 Severe Splenomegaly
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Splenomegaly Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Splenomegaly Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Splenomegaly Therapeutics Market Size Forecast by Type
13.6.1 Drug Therapy
13.6.2 Vaccination
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Splenomegaly Therapeutics Market Size Forecast by Applications
13.10.1 Normal (Not Splenomegaly)
13.10.2 Moderate Splenomegaly
13.10.3 Severe Splenomegaly
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Splenomegaly Therapeutics Market: Competitive Dashboard
14.2 Global Splenomegaly Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline plc
14.3.2 Incyte Corporation
14.3.3 Merck & Co., Inc.
14.3.4 Novartis AG
14.3.5 Sanofi
